BACKGROUND: Cold atmospheric plasma( @entity9527 ) have shown promises for wound healing though little is understood of underpinning mechanisms. Little has been reported so far of their potential treatment of immune-mediated diseases such as @entity1569 . OBJECTIVES: To study @entity9527 -induced cell death and in cytokine release of @entity1 keratinocytes as a first assessment of possible @entity9527 use for @entity1569 . METHODS: Using a @entity9527 generator free of energetic ions, we observed its effects on keratinocytes in morphology, cell viability and apoptosis, intracellular and mitochondrial ROS, lysosomal integrity and mitochondrial membrane potential, and on secretion and expression of eight cytokines at protein and gene level. RESULTS: @entity9527 induced reduced cell viability, apoptotic death, and production of intracellular and mitochondrial ROS in a dose-dependent matter. @entity2383 and lysosomal leakage were found in @entity9527 treated cells. It also induced release of @entity650 , @entity687 , @entity5 @entity39 factor(TNF)-a and vascular endothelial growth factor( @entity7 ), and enhanced the mRNA expression of @entity1356 , @entity650 , @entity687 , @entity688 , @entity310 , @entity379 and @entity7 . By contrast, IL-12 declined monotonically. CONCLUSIONS: The results suggest that with appropriate control of its dose physical plasma could induce cell death via apoptotic pathway and enable simultaneous reduction in IL-12. These may be used to suppress keratinocyte hyperproliferation and to target T cell activation for controlling amplification of @entity32 , respectively. This provides an initial basis for further studies of @entity9527 as potential therapeutics for inflammatory and immune-related diseases in dermatology including @entity1569 . This article is protected by copyright. All rights reserved.

Surface air plasma induced cell death and cytokines release of @entity1 keratinocytes in the context of XXXX .

@entity1 :: ('9606', 'Species') :: ['human'] @entity650 :: ('3569', 'Gene') :: ['IL-6', 'interleukin(IL)-6'] @entity32 :: ('MESH:D007249', 'Disease') :: ['inflammation'] @entity1569 :: ('MESH:D011565', 'Disease') :: ['psoriasis'] @entity39 :: ('MESH:D009336', 'Disease') :: ['necrosis'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor'] @entity7 :: ('7422', 'Gene') :: ['VEGF'] @entity1356 :: ('3553', 'Gene') :: ['IL-1b'] @entity310 :: ('7124', 'Gene') :: ['TNF-a'] @entity379 :: ('3458', 'Gene') :: ['IFN-y'] @entity9527 :: ('OMIM:115650', 'Disease') :: ['CAP'] @entity687 :: ('3576', 'Gene') :: ['IL-8'] @entity688 :: ('3586', 'Gene') :: ['IL-10'] @entity2383 :: ('MESH:D028361', 'Disease') :: ['Mitochondrial dysfunction']
@entity1569 :: (MESH:D011565,Disease) :: ['psoriasis']
